CytoMed Therapeutics Limited - Enterprise Value

The Enterprise Value as of June 2026 (TTM) for CytoMed Therapeutics Limited (GDTC) is 15.20M

According to CytoMed Therapeutics Limited’s latest financial reports and current stock price. The company's current Enterprise Value is 15.20M. This represents a change of -53.73% compared to the average of 32.84M of the last 4 quarters.

CytoMed Therapeutics Limited (GDTC) Historical Enterprise Value (quarterly & annually)

How has GDTC Enterprise Value performed in the past?

The mean historical Enterprise Value of CytoMed Therapeutics Limited over the last ten years is 39.20M. The current 15.20M Enterprise Value has changed 3.78% with respect to the historical average. Over the past ten years (40 quarters), GDTC's Enterprise Value was at its highest in in the December 2023 quarter at 66.02M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

CytoMed Therapeutics Limited (GDTC) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of CytoMed Therapeutics Limited Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

CytoMed Therapeutics Limited (GDTC) Average Enterprise Value

How has GDTC Enterprise Value performed in the past?

The current Enterprise Value of CytoMed Therapeutics Limited (GDTC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

CytoMed Therapeutics Limited (GDTC) Enterprise Value vs. Peers

How is GDTC’s Enterprise Value compared to its peers?

CytoMed Therapeutics Limited’s Enterprise Value is greater than Enlivex Therapeutics Ltd. (13.74M), greater than MetaVia Inc. (-10014683.00), greater than NuCana plc (-12088566.93), less than NeuroSense Therapeutics Ltd. (19.85M), less than Lisata Therapeutics, Inc. (18.99M), greater than CollPlant Biotechnologies Ltd. (2.51M), less than NeurAxis, Inc. (81.82M), greater than Passage Bio, Inc. (-9649342.00), greater than Exicure, Inc. (12.14M), greater than Sonnet BioTherapeutics Holdings, Inc. (3.36M),

Build a custom stock screener for CytoMed Therapeutics Limited (GDTC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CytoMed Therapeutics Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

CytoMed Therapeutics Limited (GDTC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like CytoMed Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.